Posted by Michael Wonder on 07 Jul 2021
Valneva awarded FDA breakthrough designation for its single-shot Chikungunya vaccine candidate
7 July 2021 - This new U.S. milestone follows FDA fast track and EMA PRIME designations.
Valneva today announced that it has been awarded breakthrough therapy designation for its single-shot chikungunya vaccine candidate, VLA1553, by the U.S. FDA.
